Enzymatica
1.88 SEK
-3.34 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-3.34 %
-3.59 %
-18.97 %
-35.62 %
+18.99 %
+7.43 %
-53.79 %
-89.75 %
-67.09 %
Enzymatica is a life science company that develops and sells medical devices against infectious diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and shorten the duration of the illness. The product has been launched in several markets and the strategy is to expand to more markets through partners. The head office is located in Lund.
Read moreMarket cap
456.34M SEK
Turnover
83.04K SEK
Revenue
45.58M
EBIT %
-114.22 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.2
2026
Annual report '25
28.4
2026
Interim report Q1'26
7.5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance
BioStock: Enzymatica’s CEO steps down after four years – summarizes a journey from science to commercialization
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools